Pfizer Inc. (PFE)
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market.
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer vs Eli Lilly: Different Bets on Pharma M&A
Pfizer (NYSE: PFE | PFE Price Prediction) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma.
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth
Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.
Pfizer beats Q1 revenue and profit estimates, reaffirms 2026 guidance
Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on Tuesday, driven by strong growth in its launched and acquired products, as the drugmaker reaffirmed its full-year financial outlook. The pharmaceutical giant posted revenue of $14.5 billion for the quarter ended March 31, up 5% from a year earlier and ahead of analyst estimates of $13.84 billion.
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Pfizer (PFE) Q1 Earnings and Revenues Top Estimates
Pfizer (PFE) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.92 per share a year ago.
Pfizer Posts Better-Than-Expected Revenue, Profit
Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.
Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending
Pfizer posted higher first-quarter revenue but lower profit that was weighed down partially by higher research and development spending.
Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates
The drugmaker has been leaning on recently acquired products to offset a looming patent cliff.
Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth
Pfizer posted first-quarter earnings and revenue that topped estimates and reaffirmed its 2026 outlook, as recently launched and acquired products showed growth. The pharmaceutical giant is looking to longer-term investments in its pipeline, including its recent $10 billion acquisition of the obesity biotech Metsera, to counter waning Covid product sales and declines from older drugs.
Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis
Pfizer on Tuesday reported first-quarter profit above Wall Street estimates, boosted by sustained demand for older drugs such as blood thinner Eliquis.
